Introduction

Ayalew Tefferi

Divisions of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn., USA

A set of seminal observations, in 2002 and 2003, has ignited major interest in the science and practice of eosinophilic disorders and systemic mastocytosis (SM) [1–4]. It all started with the clinical observation that imatinib mesylate produced impressive responses in both ‘hypereosinophilic syndrome (HES)’ [1] and SM [2], in the absence of the *bcr/abl* oncoprotein. This was followed by the discovery of the specific drug target in both instances, *FIP1L1-PDGFR* [3]. A large clinical study has subsequently demonstrated that the dramatic treatment responses to low-dose imatinib mesylate (100 mg/day) occurred only in the presence of the *FIP1L1-PDGFR* mutation, and that the phenotype that was linked to the particular genotype was SM associated with prominent blood eosinophilia (SM-eos) [5]. Also in 2002, imatinib mesylate was shown to be effective in a related, eosinophilia-associated myeloproliferative disorder that was characterized by a mutation in the other PDGFR gene, *PDGFRB* [4]. The latter appeared to be always associated with a microscopically detectable cytogenetic lesion involving chromosome 5q33 [6], while *FIP1L1-PDGFR* is cytogenetically occult [3].

The above-mentioned developments have led to the reclassification of both eosinophilic disorders and SM into treatment-relevant categories [7, 8]. In this regard, it is important to note that imatinib mesylate is ineffective, both in vitro and in vivo, against D816V *c-kit*-mutated SM as well as the majority of patients with true HES [5, 9, 10]. In the former instance, it is hoped that the problem will be overcome by the therapeutic utilization of second-generation kinase inhibitors that have shown in vitro activity against D816V *c-kit*-mutated cell lines [11, 12]. These and other similarly acting drugs [11, 13] might also show enhanced therapeutic activity in molecularly undefined HES. Another drug that has been shown to have excellent clinical activity in SM is cladribine, although the mechanism of action has not been well delineated [14–16]. Despite the aforementioned major advances, much remains to be discovered in terms of both pathogenesis and treatment of SM and HES. In the current mini-symposium, my colleagues and I have summarized the current state of knowledge in the biology, classification, and treatment of primary eosinophilic disorders, including HES and SM.

References

- 1 Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH: Treatment of hypereosinophilic syndrome with imatinib mesylate. *Lancet* 2002;359:1577–1578.
- 2 Pardanani A, Elliott M, Reeder T, Li CY, Baxter EJ, Cross NC, Tefferi A: Imatinib for systemic mast-cell disease. *Lancet* 2003;362:535–536.
- 3 Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG: A tyrosine kinase created by fusion of the PDGFR and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. *N Engl J Med* 2003;348:1201–1214.
- 4 Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silberman S, Schultheis B, Cross NC, Goldman JM: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. *N Engl J Med* 2002;347:481–487.

- 5 Pardanani A, Brockman SR, Paternoster SF, Flynn HC, Ketterling RP, Lasho TL, Ho CL, Li CY, Dewald GW, Tefferi A: FIP1L1-PDG-FRA fusion: Prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. *Blood* 2004;104:3038–3045.
- 6 Steer EJ, Cross NC: Myeloproliferative disorders with translocations of chromosome 5q31–35: Role of the platelet-derived growth factor receptor Beta. *Acta Haematol* 2002;107:113–122.
- 7 Tefferi A: Blood eosinophilia: A new paradigm in disease classification, diagnosis, and treatment. *Mayo Clin Proc* 2005;80:75–83.
- 8 Tefferi A, Pardanani A: Clinical, genetic, and therapeutic insights into systemic mast cell disease. *Curr Opin Hematol* 2004;11:58–64.
- 9 Akin C, Brockow K, D'Ambrosio C, Kirshenbaum AS, Ma Y, Longley BJ, Metcalfe DD: Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. *Exp Hematol* 2003;31:686–692.
- 10 Pardanani A, Tefferi A: Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. *Blood* 2004;104:1931–1939.
- 11 Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL: Overriding imatinib resistance with a novel ABL kinase inhibitor. *Science* 2004;305:399–401.
- 12 Doggrell SA: BMS-354825: A novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia. *Expert Opin Investig Drugs* 2005;14:89–91.
- 13 Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Mohammed A, Neuberg D, Wright RD, Gilliland DG, Griffin JD: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. *Cancer Cell* 2005;7:129–141.
- 14 Tefferi A, Li CY, Butterfield JH, Hoagland HC: Treatment of systemic mast-cell disease with cladribine. *N Engl J Med* 2001;344:307–309.
- 15 Kluin-Nelemans HC, Oldhoff JM, van Doormaal JJ, Van 't Wout JW, Verhoef G, Gerrits WB, van Dobbenburgh OA, Pasmans SG, Fijnheer R: Cladribine therapy for systemic mastocytosis. *Blood* 2003;102:4270–4276.
- 16 Pardanani A, Hoffbrand AV, Butterfield JH, Tefferi A: Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. *Leuk Res* 2004;28:127–131.